Biener, Moritz
Giannitsis, Evangelos
Hogrefe, Katharina
Mueller-Hennessen, Matthias
Fröhlich, Hanna
Katus, Hugo A.
Frey, Norbert
Frankenstein, Lutz
Täger, Tobias
Clinical trials referenced in this document:
Documents that mention this clinical trial
Risk prediction in stable cardiovascular disease using a high-sensitivity cardiac troponin T single biomarker strategy compared to the ESC-SCORE (Pre-results)
https://doi.org/10.1136/openhrt-2017-000710
Prognostic value of changes in high-sensitivity cardiac troponin T beyond biological variation in stable outpatients with cardiovascular disease: a validation study
https://doi.org/10.1007/s00392-021-01952-6
Funding for this research was provided by:
Universitätsklinikum Heidelberg
Article History
Received: 26 June 2021
Accepted: 13 October 2021
First Online: 25 October 2021
Declarations
:
: M.B. reports grants and non-financial support from AstraZeneca, non-financial support from Brahms Thermo Fisher, outside the submitted work; E.G. reports grants, personal fees and non-financial support from Roche Diagnostics, grants, personal fees and non-financial support from AstraZeneca, grants, personal fees and non-financial support from Bayer Vital, grants, personal fees and non-financial support from Brahms Thermo Fisher, personal fees from Daiichi Sankyo, personal fees from Boehringer Ingelheim, outside the submitted work. M.M.-H., reports research support by the Medical Faculty of Heidelberg University, research support from Roche Diagnostics and BRAHMS Thermo Scientific, speaker honoraria from Roche Diagnostics, non-financial support by BRAHMS Thermo Scientific, Bayer Vital GmbH, Daiichi-Sankyo, Metanomics Health GmbH and Philips Electronics, outside the submitted work. All the other authors have nothing to disclose. HAK received honoraria for lecturers from Roche Diagnostics, AstraZeneca, Bayer Vital, Daiichi-Sankyo, and held a patent on cTnT that has expired. All the other authors have no conflicts of interest to declare.